Top

Published in:

01-07-2016 | Original Article

Elevated serum microRNA-122/222 levels are potential diagnostic biomarkers in Egyptian patients with chronic hepatitis C but not hepatic cancer

Authors: Tarek M. K. Motawi, Nermin A. H. Sadik, Olfat G. Shaker, Maggy H. Ghaleb

Published in: Tumor Biology | Issue 7/2016

Abstract

MicroRNAs (miRNAs) are a class of endogenous small non-coding RNAs that regulate gene expression at the post-transcriptional level. Because of their size, specificity, and relative stability in plasma, miRNAs can be used as diagnostic and prognostic biomarkers to monitor liver injury, such as that caused by hepatitis C virus (HCV) and liver cancer. In this study, we investigated miRNA expression patterns from the serum of Egyptian patients with HCV and liver cancer compared with matched healthy controls. Using microarray-based expression profiling followed by real-time quantitative polymerase chain reaction validation, we compared the levels of circulating miRNA-122 and miRNA-222 in serum from patients with hepatitis C virus (n = 40) and liver cancer (n = 60) to matched healthy controls (n = 30). MiRNA SNORD68 was the housekeeping endogenous control. We found that the serum levels of miR-122 and miR-222 were significantly elevated in HCV patients, but not in liver cancer patients, compared with controls. Receiver operating characteristic analysis revealed that miR-122 and miR-222 have a high diagnostic potential in discriminating patients with HCV from controls. Serum miR-222 was significantly higher in HCV patients compared to liver cancer patients. Our results indicate that serum miR-122 and miR-222 are elevated in Egyptian patients with chronic HCV, and these miRNAs have a strong potential to serve as novel biomarkers for liver injury but not specifically for liver cancer.

Ikeda K, Saitoh S, Suzuki Y, Kobayashi M, Tsubota A, Koida I, et al. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. J Hepatol. 1998;28(6):930–8.CrossRefPubMed

Deuffic-Burban S, Mohamed MK, Larouze B, Carrat F, Valleron AJ. Expected increase in hepatitis C-related mortality in Egypt due to pre-2000 infections. J Hepatol. 2006;44(3):455–61.CrossRefPubMed

Nguyen MH, Keeffe EB. Prevalence and treatment of hepatitis C virus genotypes 4, 5, and 6. Clin Gastroenterol Hepatol. 2005;3 Suppl 2:S97–101.CrossRefPubMed

Egyptian Ministry of Health. Egyptian Ministry of Health Annual Report MOHP, 2007 http://www.mohp.gov.eg/Main.asp.

Abdel-Aziz F, Habib M, Mohamed MK, Abdel-Hamid M, Gamil F, Madkour S, et al. Hepatitis C virus (HCV) infection in a community in the Nile Delta: population description and HCV prevalence. Hepatology. 2000;32:111–5.CrossRefPubMed

Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.CrossRefPubMed

Kudo M. Hepatocellular carcinoma in 2011 and beyond: from the pathogenesis to molecular targeted therapy. Oncology. 2011;81 Suppl 1:1–10.CrossRefPubMed

Meguro M, Mizuguchi T, Kawamoto M, Hirata K .The molecular pathogenesis and clinical implications of hepatocellular carcinoma.Int J Hepatol. 2011; 818672.doi: 10.4061/2011/818672.

Yamazaki K, Masugi Y, Sakamoto M. Molecular pathogenesis of hepatocellular carcinoma: altering transforming growth factor-beta signaling in hepatocarcinogenesis. Dig Dis. 2011;29(3):284–8. doi:10.1159/000327560.CrossRefPubMed

10.

Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2011;94(2):153–6.CrossRef

11.

Yu MC, Yuan JM, Govindarajan S, Ross RK. Epidemiology of hepatocellular carcinoma. Can J Gastroenterol. 2000;14(8):703–9.CrossRefPubMed

12.

National Cancer Registry of Egypt. Magnitude of hepatocellular carcinoma in Egypt NCI, 2007 http://www.nci.edu.eg.

13.

Freedman LS, Edwards BK, Ries LAG, Young JL (eds.). Cancer incidence in four member countries (Cyprus, Egypt, Israel, and Jordan) of the Middle East Cancer Consortium (MECC) compared with US SEER. 2006; NIH Pub. No. 06–5873. Bethesda: National Cancer Institute

14.

Chen X, Leung SY, Yuen ST, Chu KM, Ji J, Li R, et al. Variation in gene expression patterns in human gastric cancers. Mol Biol Cell. 2003;14(8):3208–15. doi:10.1091/mbc.E02-12-0833.CrossRefPubMedPubMedCentral

15.

Liu J, Carmell MA, Rivas FV, Marsden CG, Thomson JM, Song JJ, et al. Argonaute2 is the catalytic engine of mammalian RNAi. Science. 2004;305(5689):1437–41.CrossRefPubMed

16.

Neilson JR, Sharp PA. Small RNA regulators of gene expression. Cell. 2008;134(6):899–902. doi:10.1016/j.cell.2008.09.006.CrossRefPubMed

17.

Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120:15–20.CrossRefPubMed

18.

Kloosterman WP, Plasterk RH. The diverse functions of microRNAs in animal development and disease. Dev Cell. 2006;11(4):441–50.CrossRefPubMed

19.

Stefani G, Slack FJ. Small noncoding RNAs in animal development. Nat Rev Mol Cell Biol. 2008;9(3):219–30. doi:10.1038/nrm2347.CrossRefPubMed

20.

Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75(5):843–54.CrossRefPubMed

21.

Lujambio A, Lowe SW. The microcosmos of cancer. Nature. 2012;482(7385):347–55. doi:10.1038/nature10888.CrossRefPubMedPubMedCentral

22.

Hummel R, Hussey DJ, Haier J. MicroRNAs: predictors and modifiers of chemo- and radiotherapy in different tumour types. Eur J Cancer. 2010;46(2):298–311. doi:10.1016/j.ejca.2009.10.027.CrossRefPubMed

23.

Bai S, Nasser MW, Wang B, Hsu SH, Datta J, Kutay H, et al. MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. J Biol Chem. 2009;284(46):32015–27. doi:10.1074/jbc.M109.016774.CrossRefPubMedPubMedCentral

24.

Tsai WC, Hsu PW, Lai TC, Chau GY, Lin CW, Chen CM, et al. MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. Hepatology. 2009;49(5):1571–82. doi:10.1002/hep.22806.CrossRefPubMed

25.

Coulouarn C, Factor VM, Andersen JB, Durkin ME, Thorgeirsson SS. Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene. 2009;28(40):3526–36. doi:10.1038/onc.2009.211.CrossRefPubMedPubMedCentral

26.

Le Sage C, Nagel R, Egan DA, Schrier M, Mesman E, Mangiola A, et al. Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. Embo J. 2007;26:3699–708.CrossRefPubMedPubMedCentral

27.

Ogawa T, Enomoto M, Fujii H, Sekiya Y, Yoshizato K, Ikeda K, et al. MicroRNA-221/222 upregulation indicates the activation of stellate cells and the progression of liver fibrosis. Gut. 2012;61(11):1600–9.CrossRefPubMed

28.

Krützfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M, et al. Silencing of microRNAs in vivo with “antagomirs”. Nature. 2005;438(7068):685–9.CrossRefPubMed

29.

Kutay H, Bai S, Datta J, Motiwala T, Pogribny I, Frankel W, et al. Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. J Cell Biochem. 2006;99(3):671–8.CrossRefPubMedPubMedCentral

30.

Xu Y, Xia F, Ma L, Shan J, Shen J, Yang Z, et al. MicroRNA-122 sensitizes HCC cancer cells to adriamycin and vincristine through modulating expression of MDR and inducing cell cycle arrest. Cancer Lett. 2011;310(3):160–9. doi:10.1016/j.canlet.2011.06.027.PubMed

31.

Child CG, Turcotte JG. Surgery and portal hypertension. Major Probl Clin Surg. 1964;1:1–85.PubMed

32.

Barshack I, Lithwick-Yanai G, Afek A, Rosenblatt K, Tabibian-Keissar H, Zepeniuk M, et al. MicroRNA expression differentiates between primary lung tumors and metastases to the lung. Pathol Res Pract. 2010;206(8):578–84. doi:10.1016/j.prp.2010.03.005.CrossRefPubMed

33.

Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2 (−delta delta C (T)) method. Methods. 2001;25(4):402–8.CrossRefPubMed

34.

Carthew RW, Sontheimer EJ. Origins and mechanisms of miRNAs and siRNAs. Cell. 2009;136(4):642–55. doi:10.1016/j.cell.2009.01.035.CrossRefPubMedPubMedCentral

35.

Mott JL, Kobayashi S, Bronk SF, Gores GJ. Mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene. 2007;26(42):6133–40. doi:10.1038/sj.onc.1210436.CrossRefPubMedPubMedCentral

36.

Kanda T, Ishibashi O, Kawahigashi Y, Mishima T, Kosuge T, Mizuguchi Y, et al. Identification of obstructive jaundice-related microRNAs in mouse liver. Hepatogastroenterology. 2010;57(102–103):1013–23.PubMed

37.

Roderburg C, Urban GW, Bettermann K, Vucur M, Zimmermann H, Schmidt S, et al. Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis. Hepatology. 2011;53:209–18. doi:10.1002/hep.23922.CrossRefPubMed

38.

Huang J, Wang Y, Guo Y, Sun S. Down-regulated microRNA-152 induces aberrant DNA methylation in hepatitis B virus-related hepatocellular carcinoma by targeting DNA methyltransferase 1. Hepatology. 2010;52:60–70. doi:10.1002/hep.23660.CrossRefPubMed

39.

Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008;105(30):10513–8. doi:10.1073/pnas.0804549105.CrossRefPubMedPubMedCentral

40.

Laterza OF, Lim L, Garrett-Engele PW, Vlasakova K, Muniappa N, Tanaka WK, et al. Plasma MicroRNAs as sensitive and specific biomarkers of tissue injury. Clin Chem. 2009;55(11):1977–83. doi:10.1373/clinchem.2009.131797.CrossRefPubMed

41.

Kosaka N, Iguchi H, Yoshioka Y, Takeshita F, Matsuki Y, Ochiya T. Secretory mechanisms and intercellular transfer of microRNAs in living cells. J Biol Chem. 2010;285(23):17442–52. doi:10.1074/jbc.M110.107821.CrossRefPubMedPubMedCentral

42.

Gallo A, Tandon M, Alevizos I, Illei GG. The majority of microRNAs detectable in serum and saliva is concentrated in exosomes. PLoS One. 2012;7(3), e30679. doi:10.1371/journal.pone.0030679.CrossRefPubMedPubMedCentral

43.

Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007;9(6):654–9.CrossRefPubMed

44.

Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P. Modulation of hepatitis C virus RNA abundance by a liver-specific microRNA. Science. 2005;309(5740):1577–81.CrossRefPubMed

45.

Chang J, Guo JT, Jiang D, Guo H, Taylor JM, Block TM. Liver-specific microRNA miR-122 enhances the replication of hepatitis C virus in nonhepatic cells. J Virol. 2008;82(16):8215–23. doi:10.1128/JVI.02575-07.CrossRefPubMedPubMedCentral

46.

Xu J, Wu C, Che X, Wang L, Yu D, Zhang T, et al. Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog. 2011;50(2):136–42. doi:10.1002/mc.20712.CrossRefPubMed

47.

Jopling CL. Regulation of hepatitis C virus by microRNA-122. Biochem Soc Trans. 2008;36(pt 6):1220–3. doi:10.1042/BST0361220.CrossRefPubMed

48.

Henke JI, Goergen D, Zheng J, Song Y, Schüttler CG, Fehr C, et al. MicroRNA-122 stimulates translation of hepatitis C virus RNA. EMBO J. 2008;27(24):3300–10. doi:10.1038/emboj.2008.244.CrossRefPubMedPubMedCentral

49.

Machlin ES, Sarnow P, Sagan SM. Masking the 5′ terminal nucleotides of the hepatitis C virus genome by an unconventional microRNA-target RNA complex. Proc Natl Acad Sci U S A. 2011;108(8):3193–8. doi:10.1073/pnas.1012464108.CrossRefPubMedPubMedCentral

50.

Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, Tuschl T. Identification of tissue-specific microRNAs from mouse. Curr Biol. 2002;12(9):735–9.CrossRefPubMed

51.

Chang J, Nicolas E, Marks D, Sander C, Lerro A, Bnendra MA, et al. Mir-122, a mammalian liver-specific microRNA, is processed from her mRNA and may down regulate the high affinity cationic amino acid transporter CAT-1. RNA Biol. 2004;1(2):106–13.CrossRefPubMed

52.

Lin CJ, Gong HY, Tseng HC, Wang WL, Wu JL. miR-122 targets an anti-apoptotic gene, Bcl-w, in human hepatocellular carcinoma cell lines. Biochem Biophys Res Commun. 2008;375(3):315–20. doi:10.1016/j.bbrc.2008.07.154.CrossRefPubMed

53.

Esau C, Davis S, Murray SF, Yu XX, Pandey SK, Pear M, et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab. 2006;3(2):87–98.CrossRefPubMed

54.

Gatfield D, Le Martelot G, Vejnar CE, Gerlach D, Schaad O, Fleury-Olela F, et al. Integration of microRNA miR-122 in hepatic circadian gene expression. Genes Dev. 2009;23(11):1313–26. doi:10.1101/gad.1781009.CrossRefPubMedPubMedCentral

55.

Castoldi M, VujicSpasic M, Altamura S, Elmén J, Lindow M, Kiss J, et al. The liver-specific microRNA miR-122 controls systemic iron homeostasis in mice. J Clin Invest. 2011;121(4):1386–96. doi:10.1172/JCI44883.CrossRefPubMedPubMedCentral

56.

Kim N, Kim H, Jung I, Kim Y, Kim D, Han YM. Expression profiles of miRNAs in human embryonic stem cells during hepatocyte differentiation. Hepatol Res. 2011;41(2):170–83. doi:10.1111/j.1872-034X.2010.00752.x.CrossRefPubMed

57.

Galardi S, Mercatelli N, Farace MG, Ciafrè SA. NF-kB and c-Jun induce the expression of the oncogenic miR-221 and miR-222 in prostate carcinoma and glioblastoma cells. Nucleic Acids Res. 2011;39(9):3892–902. doi:10.1093/nar/gkr006.CrossRefPubMedPubMedCentral

58.

Lee KS, Buck M, Houglum K, Chojkier M. Activation of hepatic stellate cells by TGF alpha and collagen type I is mediated by oxidative stress through c-myb expression. J Clin Invest. 1995;96(5):2461–8.CrossRefPubMedPubMedCentral

59.

Rippe RA, Schrum LW, Stefanovic B, Solís-Herruzo JA, Brenner DA. NF-kappaB inhibits expression of the alpha 1(I) collagen gene. DNA Cell Biol. 1999;18(10):751–61.CrossRefPubMed

60.

Lang A, Schoonhoven R, Tuvia S, Brenner DA, Rippe RA. Nuclear factor kappaB in proliferation, activation and apoptosis in rat hepatic stellate cells. J Hepatol. 2000;33:49–58.CrossRefPubMed

61.

Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem. 2000;275(4):2247–50.CrossRefPubMed

62.

Kawada N. Evolution of hepatic fibrosis research. Hepatol Res. 2011;41(3):199–208. doi:10.1111/j.1872-034X.2011.00776.x.CrossRefPubMed

63.

Mazzocca A, Carloni V, Sciammetta S, Cordella C, Pantaleo P, Caldini A, et al. Expression of transmembrane 4 superfamily (TM4SF) proteins and their role in hepatic stellate cell motility and wound healing migration. J Hepatol. 2002;37(3):322–30.CrossRefPubMed

64.

Cormier EG, Tsamis F, Kajumo F, Durso RJ, Gardner JP, Dragic T. CD81 is an entry coreceptor for hepatitis C virus. Proc Natl Acad Sci U S A. 2004;101(19):7270–4.CrossRefPubMedPubMedCentral

65.

Mazzocca A, Sciammetta SC, Carloni V, Cosmi L, Annunziato F, Harada T, et al. Binding of hepatitis C virus envelope protein E2 to CD81 up-regulates matrix metalloproteinase-2 in human hepatic stellate cells. J Biol Chem. 2005;280(12):11329–39.CrossRefPubMed

66.

Bataller R, Paik YH, Lindquist JN, Lemasters JJ, Brenner DA. Hepatitis C virus core and nonstructural proteins induce fibrogenic effects in hepatic stellate cells. Gastroenterology. 2004;126(2):529–40.CrossRefPubMed

67.

Gramantieri L, Ferracin M, Fornari F, Veronese A, Sabbioni S, Liu CG, et al. Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res. 2007;67(13):6092–9.CrossRefPubMed

68.

Fornari F, Gramantieri L, Giovannini C, Veronese A, Ferracin M, Sabbioni S, et al. MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res. 2009;69(14):5761–7. doi:10.1158/0008-5472.CAN-08-4797.CrossRefPubMed

69.

Wu X, Wu S, Tong L, Luan T, Lin L, Lu S, et al. miR-122 affects the viability and apoptosis of hepatocellular carcinoma cells. Scand J Gastroenterol. 2009;44(11):1332–9. doi:10.3109/00365520903215305.CrossRefPubMed

70.

Pineau P, Volinia S, McJunkin K, Marchio A, Battuston C, Terris B, et al. miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci USA. 2010;107:264–9. doi:10.1073/pnas.0907904107.CrossRefPubMed

71.

Fuse M, Kojima S, Enokida H, Chiyomaru T, Yoshino H, Nohata N, et al. Tumor suppressive microRNAs (miR-222 and miR-31) regulate molecular pathways based on miRNA expression signature in prostate cancer. J Hum Genet. 2012;57(11):691–9. doi:10.1038/jhg.2012.95.CrossRefPubMed

72.

Xiao L, Cui YH, Rao JN, Zou T, Liu L, Smith A, et al. Regulation of cyclin-dependent kinase 4 translation through CUG-binding protein 1 and microRNA-222 by polyamines. Mol Biol Cell. 2011;22:3055–69. doi:10.1091/mbc.E11-01-0069.CrossRefPubMedPubMedCentral

73.

Casero RA, Pegg AE. Polyamine catabolism and disease. Biochem J. 2009;421(3):323–38. doi:10.1042/BJ20090598.CrossRefPubMedPubMedCentral

74.

Eisenberg T, Knauer H, Schauer A, Büttner S, Ruckenstuhl C, Carmona-Gutierrez D, et al. Induction of autophagy by spermidine promotes longevity. Nat Cell Biol. 2009;11(11):1305–14. doi:10.1038/ncb1975.CrossRefPubMed

75.

Reed SI. Control of the G1/S transition. Cancer Surv. 1997;29:7–23.PubMed

76.

Tsutsui T, Hesabi B, Moons DS, Pandolfi PP, Hansel KS, Koff A, et al. Targeted disruption of CDK4 delays cell cycle entry with enhanced p27 (Kip1) activity. Mol Cell Biol. 1999;19(10):7011–9.CrossRefPubMedPubMedCentral

77.

Hermeking H. P53 enters the microRNA world. Cancer Cell. 2007;12(5):414–8.CrossRefPubMed

78.

Li L, Rao JN, Guo X, Liu L, Santora R, Bass BL, et al. Polyamine depletion stabilizes p53 resulting in inhibition of normal intestinal epithelial cell proliferation. Am J Physiol Cell Physiol. 2001;281(3):C941–53.PubMed

79.

Zou T, Mazan-Mamczarz K, Rao JN, Liu L, Marasa BS, Zhang AH, et al. Polyamine depletion increases cytoplasmic levels of RNA-binding protein HuR leading to stabilization of nucleophosmin and p53 mRNAs. J Biol Chem. 2006;281(28):19387–94.CrossRefPubMed

Title: Elevated serum microRNA-122/222 levels are potential diagnostic biomarkers in Egyptian patients with chronic hepatitis C but not hepatic cancer
Authors: Tarek M. K. Motawi
Nermin A. H. Sadik
Olfat G. Shaker
Maggy H. Ghaleb
Publication date: 01-07-2016
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 7/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-016-4884-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2016

A novel dual-targeted ultrasound contrast agent provides improvement of gene delivery efficiency in vitro

Understanding the CREB1-miRNA feedback loop in human malignancies

miR-143 inhibits tumor progression by targeting FAM83F in esophageal squamous cell carcinoma

NANOG regulates epithelial-mesenchymal transition and chemoresistance through activation of the STAT3 pathway in epithelial ovarian cancer

SUSD2 is frequently downregulated and functions as a tumor suppressor in RCC and lung cancer

Clinical role of HER2 gene amplification and chromosome 17: a study on 154 IHC-equivocal cases of invasive breast carcinoma patients

Keynote webinar | Spotlight on antibody–drug conjugates in cancer